BriaCell Therapeutics Corp 6-K, filed Jul 8, 2021
BriaCell Therapeutics Corp. (BCTX)
About this 6-K
BriaCell Therapeutics Corp filed this 6-K on July 8, 2021.
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2021
Commission File Number: 001-40101
BRIACELLTHERAPEUTICS CORP.
(Translation of registrant’s name into English)
Suite300 – 235 15^th^ Street
WestVancouver, BC V7T 2X1
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
| Exhibit Number | Description |
|---|---|
| 99.1 | Insider Report for Jamieson Bondarenko dated July 8, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BriaCell Therapeutics Corp. | ||
|---|---|---|
| Date:<br> July 8, 2021 | By: | /s/ William V. Williams |
| Name: | William<br> V. Williams | |
| Title: | Chief<br> Executive Officer |
Exhibit 99.1
